99 results about "Amlodipine" patented technology

The invention discloses a preparation method of perindopril amlodipine tablets, and belongs to the field of pharmacy. The perindopril amlodipine tablet is prepared from the following raw material medicines: arginine perindopril and amlodipine besylate and auxiliary materials: lactose, microcrystalline cellulose, hydrophobic colloidal silicon dioxide and magnesium stearate. The preparation method of the perindopril amlodipine tablet comprises the following steps: weighing according to the prescription amount, crushing and sieving the raw materials for pretreatment, sieving the whole particles of the auxiliary materials for pretreatment, premixing, feeding and total mixing, tabletting and the like. The prepared perindopril amlodipine tablet is relatively good in quality, high in stability and relatively few in waste products.

The invention relates to an application of a dihydropyridine compound or a salt thereof in preparation of a medicine for preventing and / or treating HPV infection, and belongs to the technical field of medicines and medicinal preparations. The invention provides application of a dihydropyridine compound or a salt thereof in preparation of a medicine for preventing and / or treating HPV (human papillomavirus) infection. The dihydropyridine compound is selected from one or more of nifedipine, amlodipine, lercanidipine, nimodipine, nitrendipine, nisoldipine, felodipine, benidipine, lacidipine and azelnidipine. According to the scheme, the application of the dihydropyridine compound or the salt thereof in prevention and / or treatment of HPV is reported for the first time, and an in-vitro cell experiment is carried out through azelnidipine in the dihydropyridine compound; furthermore, the inhibition effect on the HPV virus is verified through mouse intradermal vaccination virus model drug delivery and mouse vaginal vaccination virus model drug delivery.

The invention relates to the field of medicine preparation, in particular to a compound composition and a preparation method and application thereof. The compound composition comprises a sustained-release layer, a blocking layer and a quick-release layer, the sustained-release layer comprises metoprolol and sustained-release layer auxiliary materials, the blocking layer comprises blocking layer auxiliary materials, the quick-release layer comprises amlodipine, metoprolol and quick-release layer auxiliary materials, and the mass ratio of metoprolol of the quick-release layer to metoprolol of the sustained-release layer is (1-3): (6.5-8.5). According to the compound composition, two antihypertensive drugs with complementary action mechanisms are prepared into the long-acting compound composition which is taken once a day, amlodipine and part of metoprolol are rapidly released, the rest metoprolol is slowly released within 24 hours, and rapid antihypertensive and long-acting antihypertensive requirements are met at the same time. The composition is stable in preparation process, convenient to produce and beneficial to industrial production.

Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).

Provided herein are stable amlodipine liquid formulations. Also provided herein are methods of using amlodipine liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).

The invention belongs to the technical field of pharmaceutical preparations, and relates to an oral solid pharmaceutical composition containing irbesartan and a preparation method thereof. Irbesartan particles are prepared by adopting a wet granulation process, levamlodipine besylate particles are prepared by adopting a dry granulation process, the irbesartan particles and the levamlodipine besylate particles are mixed, a filling agent adopted in the dry granulation process is microcrystalline cellulose, and the mass ratio of irbesartan to levamlodipine besylate is (150-300): (2-4). The content uniformity of the levamlodipine besylate can meet the standard, and the stability of the composition can be improved.

The invention provides a quick-release composition, the quick-release composition contains sacubitril valsartan or a salt thereof and amlodipine or a salt thereof, and the two active components in the quick-release composition can realize quick release. The invention also relates to application of sacubitril valsartan or salt thereof, amlodipine or salt thereof and a quick-release composition thereof in preparation of medicaments for treating cardiovascular diseases.

The invention belongs to the field of medicines, and relates to a perindopril amlodipine solid preparation as well as a preparation method and application thereof. In the prior art, when an in-vitro dissolution behavior of an imitated medicine of perindopril and amlodipine tablets is investigated, it is found that the release behaviors of the perindopril and amlodipine tablets are difficult to keep consistent with those of an original developed preparation at the same time, so that the safety and effectiveness of the imitated medicine are not guaranteed. A large number of experiments find that the particle size distribution and the water content of the microcrystalline cellulose are controlled, so that the in-vitro dissolution curve of the perindopril amlodipine solid preparation is similar to that of an imported original development agent produced by an original research company, the possibility of bioequivalence with the original development agent is improved, and the drug consistency evaluation requirement is met.

The invention discloses a bisoprolol amlodipine compound tablet and a preparation process thereof, and the preparation method comprises the following steps: mixing bisoprolol or a pharmaceutically acceptable salt thereof with microcrystalline cellulose, carboxymethyl starch sodium, colloidal silicon dioxide and anhydrous citric acid according to a ratio, and carrying out dry granulation to obtain bisoprolol particles; the amlodipine or the pharmaceutically acceptable salt thereof, microcrystalline cellulose, carboxymethyl starch sodium, colloidal silicon dioxide and anhydrous citric acid are subjected to dry granulation in proportion, and amlodipine granules are obtained; the preparation method comprises the following steps: uniformly mixing bisoprolol particles and amlodipine particles, and uniformly mixing with a lubricant to obtain total mixed particles; and tabletting the total mixed particles to obtain the bisoprolol amlodipine compound tablet. According to the process, a relatively complex double-layer tablet process is not adopted, and the two active ingredients can be substantially separated, so that the operation can be effectively simplified, and the stability of the product can be improved.

The chemical structural formula of the L-glutamic acid amlodipine is as follows: # imgabs0 #, and the L-glutamic acid amlodipine is prepared by the following steps: dissolving amlodipine in an organic solvent and purified water, adding L-glutamic acid, carrying out heating reflux, naturally cooling to room temperature, introducing a refrigerant, carrying out heat preservation crystallization, carrying out suction filtration, and drying to obtain the L-glutamic acid amlodipine. Compared with the prior art, the L-glutamic acid amlodipine has the advantages that the stability is good, the L-glutamic acid amlodipine can be well applied to treatment of conditions of coronary spasm, hypertension, myocardial infarction and the like, the synthesis process is few, the L-glutamic acid amlodipine can be used for preparing L-glutamic acid amlodipine tablets, the dissolution rate of the tablets is good, the bioavailability is high, and the preparation process is simple. The bioavailability of the L-glutamic acid amlodipine is favorably improved.

The present invention discloses an amlodipine drug targeted delivery system and a preparation method thereof. The targeted delivery system can improve the targeting of amlodipine in preventing liver ischemia-reperfusion injury, and the preparation method is simple, with high feasibility and strong practicality. The amlodipine drug targeted delivery system (Am@EXOs) prepared by the present invention enables amlodipine to be distributed in the liver of a mouse model of liver ischemia-reperfusion injury, and achieves precise inhibition of calcium ion overload in liver cells with a minimum dose of amlodipine, thereby reducing cell damage, improving the targeting of amlodipine in preventing liver ischemia-reperfusion injury, and reducing the use cost of amlodipine.

Provided herein are stable amlodipine liquid formulations. Also provided herein are methods of using amlodipine liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).

The application discloses a preparation method of a capillary electrochromatography open column based on chiral induction covalent organic framework modification, a product and application thereof. The application synchronously realizes chiral induction and acid catalysis through L-(+)-tartaric acid, generates permanent helical chirality of an achiral COF skeleton by relying on a chiral memory effect, and obtains a capillary electrochromatography open column which is excellent in thermal stability, acid and alkali tolerance and cyclic regeneration performance, can baseline separate eight kinds of clinical chiral drugs with large structural differences including amlodipine, propranolol, metoprolol, chlorpheniramine, clenbuterol, terbutaline, verapamil and isopropyl epinephrine, has no attenuation in separation effect for 50 times of sample injection in succession, can be prepared in a large scale, is suitable for routine detection of drug enterprises and hospital laboratories, and directly reveals an enantiomer recognition molecular mechanism through DFT quantitative calculation, thereby providing general theoretical guidance for directional design of high-performance chiral porous interface materials.

The invention discloses a method for detecting N-nitroso benazepril impurities in levamlodipine benazepril, which comprises the following steps: grinding a benazepril hydrochloride tablet to be detected, mixing and dissolving the benazepril hydrochloride tablet with 1-methyl-2-pyrrolidone and a solvent according to the mass ratio of the effective amount of benazepril hydrochloride to the mass of 1-methyl-2-pyrrolidone of (10-50): 1, filtering, and concentrating to obtain the N-nitroso benazepril impurities in levamlodipine benazepril. Obtaining a test solution; and detecting the impurities of the N-nitroso benazepril in the test solution by adopting liquid chromatography-tandem mass spectrometry. The detection method provided by the invention is a liquid chromatography-mass spectrometry method, has the characteristics of strong specificity, high sensitivity, high accuracy and the like, and is suitable for trace detection of N-nitroso benazepril in the levamlodipine benazepril capsule preparation.

The present invention provides a composition of nebivolol and amlodipine, comprising nebivolol, amlodipine and a pharmaceutical excipient. The nebivolol comprises one or more of nebivolol, a pharmaceutically acceptable salt thereof, and a solvate thereof. The amlodipine comprises one or more of amlodipine, a pharmaceutically acceptable salt thereof, and a solvate thereof. The pharmaceutical excipient is selected from one or more of a filler, a binder, a disintegrant, a lubricant, and a glidant. The composition does not contain a colorant and a film coating. The compound preparation of the present invention has good stability, and is beneficial to improving the antihypertensive efficacy, enhancing safety and tolerability, and reducing side effects. Compared to monotherapy, the present invention reduces the number of administered medications and improves the compliance of patients, is beneficial to improving the medication compliance of the elderly patients and individuals with dysphagia, maintains a stable plasma drug concentration, maintains long-term stable blood pressure in hypertensive patients, prevents the patients from discontinuing medication arbitrarily, and prevents disease recurrence and the progression of severe complications.

An orally disintegrating tablet of amlodipine for oral administration comprising: a) amlodipine or pharmaceutically acceptable salts thereof, is present in an amount ranging from 2 to 10% w / w; b) at least one diluent; c) at least one disintegrant is present in the range from 1 to 10% w / w; d) at least one lubricant is present in the range from 0.2 to 7% w / w; e) at least one non-nutritive sweetener is present in the range from 0.1 to 7% w / w; f) at least one or more pharmaceutically acceptable excipients; wherein the ratio of combination of diluents to disintegrant is in the range from 15:1 to 40:1; and wherein orally disintegrating tablet is stable for at least three months under storage conditions of 25°C / 60% RH and 40°C / 75% RH.

The present application provides a new application of a pharmaceutical composition containing an ARNi complex, and the new application is an application of the pharmaceutical composition containing the ARNi complex in the preparation of a medicine for treating a hypertension patient who is poorly controlled by amlodipine monotherapy.

The invention relates to a coated compound tablet, in particular to a quick-release composition, which comprises a first active layer, a second active layer and a coating layer, the first active layer comprises sacubitril valsartan or a salt thereof and a pharmaceutically acceptable additive, the second active layer comprises amlodipine or a salt thereof and a pharmaceutically acceptable additive, and the coating layer is coated on the first active layer. The coating layer contains a coating material that is mainly composed of a cellulose derivative, a polyvinyl alcohol, and an aqueous acrylic resin, and the immediate release composition is capable of achieving a desired elution.

The utility model relates to the technical field of reaction kettles, and discloses a reaction kettle for preparing amlodipine besylate tablets, which comprises a reaction kettle component and a blanking component fixedly connected with the lower bottom surface of the reaction kettle component, the reaction kettle component comprises a reaction kettle body, a stirring motor is mounted at the top end of the reaction kettle body, and the stirring motor is connected with the blanking component. The discharging assembly comprises a connecting column fixedly connected with the lower bottom face of the reaction kettle body, one end of the connecting column is fixedly connected with a supporting plate, the upper surface of the supporting plate is fixedly connected with a motor, the output end of the motor is fixedly connected with a half gear, and the half gear is fixedly connected with the output end of the stirring frame. By arranging the discharging assembly, the motor is started to drive the half gear to rotate, so that the impact rod impacts the discharging pipe to generate vibration, discharging is facilitated, and meanwhile the discharging pipe is reset through the spring.

The invention provides a pharmaceutical composition. The pharmaceutical composition is prepared from enalapril, indapamide, metoprolol, amlodipine, folic acid and pharmaceutically acceptable auxiliary materials. The composition provided by the invention has the advantages that the composition has remarkable beneficial effects of reducing blood pressure and improving cardiac hemodynamics, and is particularly suitable for patients with hypertension secondary left ventricular hypertrophy and chronic heart failure. Meanwhile, the compound form of the product can improve the taking compliance of patients.

The present invention relates to a method for producing (S)-amlodipine succinate comprising reacting (S)-amlodipine (D)-hemitartrate or a solvate thereof with a first base in the presence of a two-phase solvent system comprising a first non-polar organic solvent and water to produce (S)-amlodipine base, removing the water layer, and reacting (S)-amlodipine base with succinic acid to produce (S)-amlodipine succinate. The present invention also relates to a formulation comprising (S)-amlodipine succinate.

The utility model discloses a levamlodipine besylate tablet crusher, and particularly relates to the technical field of tablet processing, the levamlodipine besylate tablet crusher comprises a crushing cavity, the top of the crushing cavity is provided with a sealing cover in a threaded manner, the bottom of the crushing cavity is provided with a charging box in a threaded manner, the sealing cover is fixedly provided with a crushing motor, and the output end of the crushing motor is fixedly provided with a rotating shaft; a first smashing cutter and a second smashing cutter are arranged at the bottom of the rotating shaft, the second smashing cutter is located at the bottom of the first smashing cutter, a dust absorption structure is arranged on the surface of the sealing cover and located on one side of the smashing motor, the dust absorption structure comprises a treatment box, and the treatment box is located on one side of the smashing cavity. According to the levamlodipine besylate tablet crushing device, levamlodipine besylate tablets can be well crushed, generated dust can be absorbed and filtered in the crushing process, the situation that dust escapes in the environment and affects operators is avoided, and the whole levamlodipine besylate tablet crushing device is convenient to disassemble, assemble and maintain.

The invention belongs to the technical field of pharmaceutical preparations, and relates to a perindopril-levamlodipine compound tablet and a preparation method thereof. The filling agent in the auxiliary materials is sieved, the sieved filling agent is divided into three parts, and the auxiliary materials do not contain lactose; mixing the perindopril arginine, docusate sodium in the auxiliary materials and the first part of filler to obtain a first premix; mixing levamlodipine besylate and a second part of filler to obtain a second premix; and uniformly mixing the first premix, the second premix and the remaining auxiliary materials, and tabletting to obtain the tablet. According to the preparation method provided by the invention, the mixing uniformity can be remarkably improved, the product quality consistency can be improved, and meanwhile, the bioavailability and the stability of the two main drugs can be improved.

The utility model discloses a synthesis reactor for levamlodipine besylate, which relates to the technical field of medical equipment, and comprises a tank body, a mounting shaft is rotatably connected in the tank body, a plurality of groups of stirring arms are fixedly connected on the outer side of the mounting shaft, and a first mounting ring and a second mounting ring are fixedly connected in the tank body. The first mounting ring is arranged above the second mounting ring, a scraping rod is arranged in the tank body, the upper end and the lower end of the scraping rod are slidably connected to the interiors of the first mounting ring and the second mounting ring correspondingly, the side face of the scraping rod is attached to the inner wall of the tank body, and a driving assembly is arranged at the top of the scraping rod; the driving assembly drives the scraping rod to do circular motion between the first installation ring and the second installation ring, in the moving process of the scraping rod, the outer side face of the scraping rod acts on the inner wall of the tank body, residues on the inner wall of the tank body are scraped away, and equipment cleaning is more convenient.

The invention relates to the technical field of medicine detection, in particular to a method for detecting N-nitroso amlodipine impurities in perindopril amlodipine tablets, which comprises the following steps: S1, preparing a test solution; s2, preparing a reference substance solution; the conditions of high performance liquid chromatography are as follows: Phenomenex Kinetex 2.6 [mu] m C18 100A is taken as a chromatographic column, a Phenomenex guard column is taken as a pre-column, an aqueous solution containing 0.1% (v / v) formic acid and 2mM ammonium acetate is taken as a mobile phase A, acetonitrile containing 0.1% (v / v) formic acid is taken as a mobile phase B, and the column temperature is 45 DEG C; and S4, performing chromatographic analysis. According to the present invention, the N-nitroso amlodipine impurity in the perindopril amlodipine tablet is determined through the high performance liquid chromatography, and the method has advantages of good specificity, good system applicability and good repeatability.

The utility model discloses a wet mixing granulator for amlodipine besylate tablets, which relates to the technical field of granulators and comprises a granulator main body, a circle of connecting net bag is fixedly connected to the top end of a sieve plate along the outer edge, a second motor is arranged in the granulator main body, the output end of the second motor is fixedly connected with a first straight cylinder, and the output end of the first straight cylinder is fixedly connected with a second straight cylinder. A second straight cylinder is arranged above the first straight cylinder, a connecting rod is fixedly connected to the top end of the second straight cylinder, a plurality of inclined ejector blocks are fixedly connected to the top end of the first straight cylinder, and a plurality of bevel grooves are formed in the bottom end of the second straight cylinder. And along with the movement of the inclined ejector block, the inclined ejector block crosses over the current bevel groove and is embedded into the next bevel groove, so that the second straight barrel moves up and down along the limiting assembly, raw materials on the sieve plate move and can smoothly pass through the sieve plate, and the sieving efficiency is improved.

The invention provides a pharmaceutical composition. The pharmaceutical composition is prepared from amlodipine, empagliflozin, folic acid substances and a pharmaceutically acceptable carrier, wherein the amlodipine, the empagliflozin and the folic acid substances are in medicinal effective dose. The invention also provides application of the pharmaceutical composition in preparation of medicines for treating lower limb artery occlusion diseases.

The invention belongs to the technical field of pharmaceutical preparations, and relates to a levoamlodipine folic acid compound tablet and a preparation process thereof, and the preparation process comprises the following steps: mixing microcrystalline cellulose with vitamin C, and enabling nitrite in the microcrystalline cellulose to be in full contact with the vitamin C to obtain a first mixture; mixing folic acid with part of the first mixture to obtain a second mixture; mixing levamlodipine besylate with the remaining first mixture to obtain a third mixture; and uniformly mixing the second mixture, the third mixture and other auxiliary materials, and tabletting to obtain the tablet. The method comprises the following steps: reacting microcrystalline cellulose with vitamin C to consume nitrite in the microcrystalline cellulose so as to prevent the nitrite from reacting with secondary amino in levamlodipine to generate nitrosamine impurities with genetic toxicity;

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to bisoprolol amlodipine tablets and a preparation method thereof. The bisoprolol amlodipine tablet is composed of a bisoprolol fumarate solid dispersion, amlodipine besylate / levamlodipine besylate, a filler, a disintegrating agent and a lubricant, the bisoprolol fumarate solid dispersion takes HPMCP as a carrier material, and triethyl citrate is added. The obtained bisoprolol and amlodipine tablet blocks the contact opportunity of bisoprolol fumarate and amlodipine, the problem of compatibility of bisoprolol fumarate and amlodipine is fundamentally solved, the storage requirement can be met without special packaging, the preparation process is simple, and the industrialization requirement is met.

The invention relates to the field of chiral drug selective release excellent enantiomers. The invention relates to a preparation method of a transdermal preparation membrane capable of selectively permeating superior enantiomers, which comprises the following steps: firstly preparing a polysulfone-based membrane containing modified silicon dioxide microspheres, then pre-acting a functional monomer and template molecules to obtain a prepolymer, adding the prepolymer into a methanol aqueous solution of the polysulfone-based membrane containing the modified silicon dioxide microspheres, and reacting to obtain the transdermal preparation membrane capable of selectively permeating superior enantiomers. And repeatedly cleaning the surface molecularly imprinted membrane with an eluent for multiple times to obtain the (S)-amlodipine molecule surface imprinted polysulfone membrane, namely the transdermal preparation membrane capable of selectively permeating excellent enantiomers. The invention also relates to an application of the transdermal preparation membrane capable of selectively permeating superior enantiomers.